Boyds is delighted to welcome Kathryn Bartley as Senior Clinical Research Associate. The appointment follows last year’s acquisition of Blue Duck Consultancy which fueled the expansion of Boyds’ in-house clinical and medical affairs services offering.
Kathryn has over 18 years’ experience in the industry, primarily in study and site management and monitoring. Her work has covered a variety of therapy areas across all trial phases within both the commercial and academic sectors.
Most recently, Kathryn spent six years working for GlaxoSmithKline (subcontracted from Parexel and then PPD) as a Senior Clinical Research Associate working primarily on real world evidence respiratory studies, including the ground-breaking Salford Lung Studies (SLS). Kathryn’s experience also includes working as a remote Clinical Research Associate on oncology trials at AstraZeneca, as well as four years as a Study Manager at the University of Liverpool Cancer Research UK Trials Unit setting up and managing haematological oncology studies.
Commenting on her appointment, Kathryn said: “Boyds is a fast-growing company with a strong reputation in the industry. I am excited to be part of their growth ambitions to expand their clinical services team. I am looking forward to working with and learning from the fantastic team of experts at Boyds, as well as building on my knowledge in advanced therapies.”
Vice President of Clinical Operations at Boyds, Dr Karen O’Hanlon added: “We are delighted to welcome Kathryn to the team. We have an established international network of consultant CRAs and our ambition is to build on this by creating an in-house team. Kathryn brings a wealth of experience and will be instrumental in supporting the growth of our clinical and medical affairs offering.
“Boyds is pretty unique in the industry offering project management and regulatory support and expertise from early stage discovery and development all the way through to clinical trials and commercialisation. Our Clinical Operations team, and network of consultant CRAs, are experienced in ATMPs and cutting-edge trials. This expertise, combined with our focus on the strategy as well as the operations in the development of medicines is an attractive offering to our clients.”
Kathryn will be based in Boyds’ Crewe office, and her role will involve performing all aspects of site set-up and management including pre-study, initiation, monitoring and closeout visits; stand-alone ethics submissions, feasibility studies, medical writing and training.